- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Valens GroWorks Corp (CSE:VGW), a BC-based, vertically-integrated provider of cannabis products, has signed a letter of intent (LOI) with Medigrowth Australia Pty. Ltd.
Valens GroWorks Corp (CSE:VGW), a BC-based, vertically-integrated provider of cannabis products, has signed a letter of intent (LOI) with Medigrowth Australia Pty. Ltd. Under the LOI, Valens with supply Medigrowth with premium cannabis flower and oil products that will then be sold and distributed across the Australian market. Valens will also be responsible for providing cultivation, extraction and lab service expertise for the support of research and development partnerships with Australian universities, governments and other organizations.
The LOI covers an initial three years, which will allow Medigrowth to apply any acquired knowledge to ongoing and future research and development opportunities.
In an article in The Province describing the LOI, Valens GroWorks CEO Tyler Robson is quoted as saying that “Medigrowth’s team is committed to investing in multidisciplinary research and development efforts with leading research institutions and governing bodies across Australia…In signing this letter of intent with Medigrowth, Valens secures a three-year supply partnership in the Australian market while strategically aligning ourselves with a company that shares in our commitment to innovation and premium product offerings to enhance patient care.”
To read the full article, click here.
Click here to connect with Valens GroWorks Corp (CSE:VGW) for an Investor Presentation.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.